

Novel Therapeutics from Modern Biotechnology

From Laboratory to Human Testing

Contributors

A. Abuchowski, R.D. Armstrong, C.F. Bennett,
J.A. Cavagnaro, D.L. Cole, S.B. Dillion, J.C. Erickson,
D.E. Everitt, S.G. Griego, G.E. Hardee, T.K. Hart,
S.P. Henry, H.E.J. Hofland, L. Huang, M.R. Koller,
H. Kotani, R.J. Kreitman, A.A. Levin, A.S. Lubiniecki,
J. Maluta, G.J. McGarrity, C.R. Middaugh, C.L. Nolan,
M.L. Nucci, W.C. Ogier, I. Pastan, R. Pearlman, T.G. Porter,
R.G. Scott, M.A. Serabian, P.J. Shadle, R.G.L. Shorr,
T.M. Smith, G.S. Srivatsa, D.W. Zabriskie

Editors

Dale L. Oxender and Leonard E. Post



Springer

Contents

CHAPTER 1

Overview of Regulatory Expectations for Introducing Novel Therapies into Clinical Trials

J.A. CAVAGNARO and M.A. SERABIAN	1
A. Introduction	1
B. Roles of Regulatory Scientists	2
C. Product Development and Availability	2
D. Data Requirements	4
E. Manufacturing	4
F. Preclinical Safety Testing	5
G. Case-By-Case Approach	6
H. Testing Goals	6
I. Study Design	7
J. Defining Exposure	7
K. Product-Specific Concerns	8
L. Accessibility of Preclinical Safety Data	9
M. Clinical Studies	10
I. Early Development	10
II. Late Development	10
N. Summary	11
References	11

CHAPTER 2

Preparation of Clinical Trial Supplies of Biopharmaceuticals

A.S. LUBINIECKI, J.C. ERICKSON, C.L. NOLAN, R.G. SCOTT, P.J. SHADLE, T.M. SMITH, and D.W. ZABRISKIE, With 1 Figure	13
A. Introduction	13
I. Research Support Systems	13
B. Preclinical Studies	13
C. Clinical Supplies	15
I. Fermentation	15
II. Harvest	17
III. Purification	18

D. Purification of rDNA-Derived Anti-RSV MAb	19
E. Product Quality Issues	22
I. Protein Purity	22
II. Protein Integrity	22
III. Microbial and Viral Safety	23
IV. Other Contaminants	23
F. Process Design and Validation	24
I. Validation of Endotoxin Removal	24
II. Process Validation of Model Virus Clearance	26
G. Process Economics and the Future of Chromatography	27
I. Process Automation and Control	27
II. Generic Purification Methods	30
H. Conclusions	31
References	31

CHAPTER 3

Proteins as Drugs: Analysis, Formulation and Delivery

C.R. MIDDAGH and R. PEARLMAN.....	33
A. Introduction	33
B. The Analysis of Protein Pharmaceuticals	34
I. X-Ray Crystallography	36
II. Nuclear Magnetic Resonance	38
III. Mass Spectroscopy	39
IV. Multiple Parametric Approaches	40
V. Miscellaneous Comments	42
C. Formulation	44
D. Delivery	49
I. Controlled-Release Dosage Forms	51
II. A Practical Delivery Challenge: Insulin	52
References	54

CHAPTER 4

Strategies for Dealing With the Immunogenicity of Therapeutic Proteins

M.L. NUCCI, R.G.L. SHORR, and A. ABUCHOWSKI	59
A. Introduction	59
B. Case Histories of Protein Therapeutic Development	61
I. Insulin	61
II. Growth Hormone	63
III. Asparaginase	64
IV. Glucocerebrosidase	65
V. OKT3	66

C. Strategies Under Development for Increasing the Therapeutic Value of Proteins and Peptides	67
I. Encapsulation	67
II. Non-Parenteral Routes of Administration	70
III. Targeting	72
IV. Conjugation	75
V. Protein Engineering	77
D. Choosing the Proper Strategy for a Protein Therapeutic	79
E. The Future of Protein Therapeutics	80
References	80

CHAPTER 5

Targeted Toxin Hybrid Proteins

R.J. KREITMAN and I. PASTAN. With 6 Figures	89
A. Introduction	89
I. Protein Toxins That Inhibit Protein Synthesis	89
1. Plant Toxins	89
2. Bacterial Toxins	89
II. Structure and Function of Pseudomonas Exotoxin	90
1. Definition of Domains and Mechanism of Intoxication	90
2. Mutants Lacking Cell Binding	91
III. Types of Toxins Made with PE	91
1. Chemical Conjugates vs Recombinant Fusions	91
2. Fusion Toxins Containing Transforming Growth Factor- α	91
3. Fusion Toxins Containing Interleukin 2	92
4. Recombinant Immunotoxins	93
B. Preclinical Development of Anti-Tac(Fv) Toxins	93
I. Background	93
II. Efficacy Data on Relevant Human Cells	94
1. Human Activated T-Lymphocytes	94
2. Fresh Adult T-Cell Leukemia Cells	95
3. Fresh Chronic Lymphocytic Leukemia Cells	96
III. Efficacy Data in an Animal Model of IL2R-Bearing Cancer	97
1. Production of the Human ATAC-4 Line	97
2. Toxicity of Anti-Tac(Fv) Toxins in Mice	97
3. Pharmacokinetics in Mice	97
4. Antitumor Activity in Tumor-Bearing Mice	98
IV. Primate Testing	99
1. Pharmacokinetics in Cynomolgus Monkeys	99
2. Toxicity in Cynomolgus Monkeys	100
V. Production Issues	100

C. Preclinical Development of Interleukin 6-PE ^{4E}	102
I. Background	102
II. Study of IL6-PE ^{4E} For Ex Vivo Marrow Purging in Multiple Myeloma	102
1. Rationale	102
2. Efficacy Against Fresh Marrow Cells from Myeloma Patients	103
3. Safety Toward Fresh Normal Marrow Cells	103
4. Safety of IL6-PE ^{4E} Toward Normal Hematopoietic Progenitors	104
5. Lack of Prevention of Bone Marrow Engraftment	104
6. Carryover of IL6-PE ^{4E} In Vivo	104
III. Production of IL6-PE ^{4E}	105
D. Summary	105
References	106

CHAPTER 6

SB 209763: A Humanized Monoclonal Antibody for the Prophylaxis and Treatment of Respiratory Syncytial Virus Infection

T.G. PORTER, S.G. GRIEGO, T.K. HART, D.E. EVERITT,

and S.B. DILLON. With 4 Figures

A. Introduction	111
B. Early Challenges in the Development of SB 209763	112
I. Selection of Target Antigen	112
II. Molecular Engineering of SB 209763	113
III. Production	114
IV. Primary Structure Analysis	115
C. Preclinical Evaluation Prior to Testing in Humans	115
I. Fusion Inhibition: An In Vitro Correlate of Protection	116
II. Antigenic Variation	119
III. Animal Models of Respiratory Syncytial Virus Infection	119
IV. Safety and Pharmacokinetics	120
D. Challenges for the Early Clinical Development of SB 209763	122
I. Selection of the Initial Study Population and Safety Considerations	122
II. Pharmacodynamic Markers to Establish Pharmacologic Effect	124
III. Formulation Considerations for Clinical Studies	124
IV. Surveillance for Anti-SB 209763 Antibodies	124
V. Transition to the Target Pediatric Population and Choice of Dose	125
VI. Results of Early Clinical Studies	125

E. Conclusion	127
References	127

CHAPTER 7

Preclinical Development of Antisense Therapeutics

A.A. LEVIN, S.P. HENRY, C.F. BENNETT, D.L. COLE, G.E. HARDEE, and G.S. SRIVATSA. With 2 Figures	131
A. Introduction	131
B. Pharmacology of Antisense Oligodeoxynucleotides	131
I. Molecular Pharmacology of Antisense Oligodeoxynucleotides	131
II. In Vivo Pharmacology of Antisense Oligodeoxynucleotides	134
C. Pharmacokinetics and Toxicity of Oligodeoxynucleotide Therapeutics	136
I. Pharmacokinetics and Metabolism	136
II. Toxicity of Phosphorothioate Oligodeoxynucleotides	142
D. Chemistry, Manufacture and Control of Phosphorothioate Oligodeoxynucleotide Drugs	147
I. Synthesis of Phosphorothioate Oligodeoxynucleotides	149
1. Chemistry of Elongation	149
2. Chemistry of Sulfurization	150
3. <i>O,O</i> -Linked Phosphorothioate DNA Diastereoisomerism	151
II. Purification of Phosphorothioate Oligodeoxynucleotides	152
III. Quality Control of Phosphorothioate Oligodeoxynucleotides	153
E. Formulation and Drug Delivery of Oligodeoxynucleotides	154
I. Physical–Chemical Properties	154
II. Formulation	155
III. Drug Delivery: Targeting, Uptake and Release	156
F. Summary	157
References	157

CHAPTER 8

Formulation and Delivery of Nucleic Acids

H.E.J. HOFLAND and L. HUANG. With 6 Figures	165
A. Introduction	165
B. Formulation of DNA	166
I. Naked-DNA Injections	166
II. Gene Guns	167
III. Polymer-Based Formulations	167

IV. Lipid-Based Formulations	171
1. Liposome Encapsulation	171
2. Cationic Lipid/Nucleotide Complex	171
3. DNA-Binding Moiety	172
4. Hydrophobic Moiety	176
5. Spacer	177
6. Linker	177
7. Helper Lipid	178
C. Delivery to Target Cells	180
D. Cell Entry	182
I. Receptor-Mediated Uptake	182
E. Endosomal Release	183
F. Nuclear Localization	185
G. Gene Expression	186
References	187

CHAPTER 9

Safe, Efficient Production of Retroviral Vectors

H. KOTANI and G.J. MCGARRITY. With 11 Figures	193
A. Introduction	193
B. Vectors	194
I. Retroviral Vectors	194
C. Production of Retroviral Vectors	196
I. Production Methods	198
1. Batch Systems	198
2. Roller Bottles	198
3. Multilayered Propagator	200
II. Bioreactors	200
1. CellCube Bioreactor	200
2. Hollow-Fiber Bioreactor	201
3. Microcarrier Beads in Bioreactor	202
4. Packed-Bed Air-Lift Bioreactor	202
5. Serum-Containing Production	203
D. Downstream Processing	207
E. GMP Production of Retroviral Vectors	208
I. Cell Banking	209
II. Serum-Free Upstream Processing	211
III. Serum-Free Downstream Processing	211
F. In-Process Assays	212
G. Quality Control	215
H. Safety	215
I. Summary and Conclusions	217
References	218

CHAPTER 10

**Clinical Systems for the Production of Cells and Tissues
for Human Therapy**

R.D. ARMSTRONG, M.R. KOLLER, J. MALUTA, and W.C. OGIER.

With 4 Figures	221
A. Introduction	221
B. Cell Therapy and Tissue Engineering	222
I. Ex Vivo Gene Therapy	223
II. Stem-Cell Therapy	223
C. Critical Requirements for Ex Vivo Cell Production	225
I. Process Reliability and Control: Automation	225
II. Process Sterility: Closed Systems	226
III. Cell Recovery	228
IV. Optimization of Key Culture Parameters by Design	228
V. Good Manufacturing Practices	230
D. Cell-Culture Devices and Procedures	231
I. Traditional Cell-Culture Processes:	
Research Laboratory Environment	232
1. Culture Flasks and Roller Bottles	233
2. Flexible Tissue Culture Containers	233
3. Bioreactors	234
II. AASTROM Cell-Production System	235
1. System Description	235
a. Disposable Cell Cassette	236
b. Incubator	237
c. Processor	237
d. System Manager	238
e. ID Key	238
E. Applications for On-Site Delivery of Therapeutic	
Cell Production	238
I. Bone-Marrow Cell Production	239
II. Other Cell and Tissue Production	239
F. Summary	240
References	240
Subject Index	243